Ocugen Inc (OCGN) Stock Price, Quote & News

Company Profile

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber c...

Industry: Biotechnology

Sector: Healthcare

Phone: 484-328-4701

Website: www.ocugen.com

Address:

11 Great Valley Parkway, Malvern, United States

Djtrush Jun. 4 at 12:52 AM

$OCGN Soon

0 · Reply

Jangalang Jun. 4 at 12:16 AM

$OCGN … We all missed the chance to dump this garbage when it was at or around $2.72. We will not see that price target again for years.

1 · Reply

coolzay Jun. 4 at 12:13 AM

$OCGN MM’s trying to get all those shares , shake the trees , OCGN is not for the weak

0 · Reply

HarryA123 Jun. 4 at 12:09 AM

$OCGN No bottom in sight.

1 · Reply

SmoldyShatStone Jun. 3 at 10:34 PM

$OCGN you gotta be a moron to believe companies actually want cures in this day and age.. big pharma is looking for treatments to keep patients on for extended periods. Why pay billions as you say to have a therapy which cures and leads to no revenue in the future and potentially removes a massive market replacing it with a cure. I know you love to pump but I guarantee you this is never going to be what you expect TomatoFarmer. Why do you think big pharma loves the obesity market? It’s a weekly injectable that will keep patients on for many many many years with millions of people constantly bringing in a revenue stream for them. A one and done approach is not ideal for ROI

1 · Reply

TheObsidiansClaw Jun. 3 at 9:58 PM

$OCGN $BETR $SAVEQ $CADL <<-->>

1 · Reply

Jangalang Jun. 3 at 9:14 PM

$OCGN … this message feed is delusional. The decline will continue until this drops far below $1.00 and they force through a reverse split.

2 · Reply

WayLoSellHi Jun. 3 at 8:59 PM

$OCGN The MM'S took us to the yearly low which considering todays overall mkt decline isn't surprising let's see this support hold till we get out of this month tiss when things get interesting as the official hands on the clock officially begin to tick for the rolling BLA submission for OCU400 🕛 "If" they're able to keep that timeline then we've got something ✅️

0 · Reply

focafoca99 Jun. 3 at 8:45 PM

$OCGN designated CFO Rita Johnson‑Greene as its new principal accounting officer after the CAO resignation. https://www.rapidticker.com/news/ocgn-sec-filing-8-k-eaaba9

0 · Reply

Lights1980 Jun. 3 at 8:24 PM

$OCGN $1.85 tomorrow.

1 · Reply

Ocugen to Participate in Upcoming June Investor and Industry Conferences

2026-05-27T11:37:17.000Z - 7 days ago

Ocugen price target lowered to $11 from $12 at Canaccord

May 26, 2026, 10:30 AM EDT - 8 days ago

Ocugen Transcript: Stifel 2026 Virtual Ophthalmology Forum

May 14, 2026, 4:30 PM EDT - 20 days ago

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

May 13, 2026, 7:02 AM EDT - 21 days ago

Ocugen to Participate in Upcoming May Scientific and Investor Conferences

2026-05-05T13:15:52.000Z - 4 weeks ago

Ocugen reports Q1 EPS (6c), consensus (5c)

May 5, 2026, 8:32 AM EDT - 4 weeks ago

Ocugen Provides Business Update with First Quarter 2026 Financial Results

May 5, 2026, 8:30 AM EDT - 4 weeks ago

Ocugen Earnings Call Transcript: Q1 2026

May 5, 2026, 8:30 AM EDT - 4 weeks ago

Ocugen Earnings release: Q1 2026

May 5, 2026, 8:30 AM EDT - 4 weeks ago

Ocugen Quarterly report: Q1 2026

May 5, 2026, 8:12 AM EDT - 4 weeks ago

Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

2026-05-04T20:16:05.000Z - 4 weeks ago

Ocugen announces private offering of $115M of convertible senior notes

May 4, 2026, 4:01 PM EDT - 4 weeks ago

Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

Apr 29, 2026, 7:02 AM EDT - 5 weeks ago

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

Apr 28, 2026, 8:00 AM EDT - 5 weeks ago

Ocugen Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 5 weeks ago

Ocugen Proxy statement: Proxy filing

Apr 23, 2026, 7:02 AM EDT - 5 weeks ago

Ocugen to Present at April 2026 Investor and Industry Conferences

Apr 20, 2026, 8:00 AM EDT - 6 weeks ago

Ocugen Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 6 weeks ago

Ocugen Proxy statement: Proxy filing

2026-04-01T11:56:15.000Z - 2 months ago

Ocugen completes dosing in GARDian3 trial

Apr 1, 2026, 7:02 AM EDT - 2 months ago

Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

2026-03-25T13:20:15.000Z - 2 months ago

Ocugen price target raised to $12 from $8 at Noble Capital

2026-03-25T10:11:21.000Z - 2 months ago

Ocugen price target raised to $10 from $7 at H.C. Wainwright

Mar 24, 2026, 8:00 AM EDT - 2 months ago

Ocugen Transcript: Study update

Mar 24, 2026, 8:00 AM EDT - 2 months ago

Ocugen Press release: Study update

2026-03-24T11:55:27.000Z - 2 months ago

Ocugen announces 12-month data from ArMaDa clinical trial of OCU410

Mar 24, 2026, 7:45 AM EDT - 2 months ago

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Mar 23, 2026, 7:02 AM EDT - 2 months ago

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

2026-03-17T11:30:27.000Z - 2 months ago

Ocugen initiated with a Buy at Canaccord

2026-03-11T10:40:53.000Z - 3 months ago

Ocugen initiated with an Outperform at Oppenheimer

2026-03-11T10:10:53.000Z - 3 months ago

Ocugen price target raised to $22 from $15 at Lucid Capital

Mar 4, 2026, 8:30 AM EST - 3 months ago

Ocugen Earnings Call Transcript: Q4 2025

Mar 4, 2026, 8:30 AM EST - 3 months ago

Ocugen Annual report: Q4 2025

Mar 4, 2026, 8:30 AM EST - 3 months ago

Ocugen Earnings release: Q4 2025

2026-03-04T13:28:15.000Z - 3 months ago

Ocugen reports Q4 EPS (6c), consensus (6c)

Mar 4, 2026, 8:15 AM EST - 3 months ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results

2026-03-02T12:34:12.000Z - 3 months ago

Ocugen announces enrollment for Phase 3 liMeliGhT trial is complete

Mar 2, 2026, 7:02 AM EST - 3 months ago

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Feb 9, 2026, 7:02 AM EST - 4 months ago

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Jan 23, 2026, 8:00 AM EST - 4 months ago

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock

Jan 21, 2026, 8:32 AM EST - 4 months ago

Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock

Jan 15, 2026, 8:30 AM EST - 4 months ago

Ocugen Transcript: Study result

Jan 15, 2026, 8:30 AM EST - 4 months ago

Ocugen Press release: Study result

Jan 15, 2026, 8:15 AM EST - 4 months ago

Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Jan 13, 2026, 7:00 AM EST - 5 months ago

Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data

Jan 12, 2026, 6:30 AM EST - 5 months ago

Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy

Jan 9, 2026, 7:02 AM EST - 5 months ago

Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference

Dec 10, 2025, 9:20 AM EST - 6 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

Nov 20, 2025, 7:02 AM EST - 6 months ago

Ocugen CEO to Present at NobleCon21—Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference

Nov 5, 2025, 8:30 AM EST - 7 months ago

Ocugen Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 7 months ago

Ocugen Quarterly report: Q3 2025

Nov 5, 2025, 8:30 AM EST - 7 months ago

Ocugen Earnings release: Q3 2025

Nov 5, 2025, 6:30 AM EST - 7 months ago

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Oct 23, 2025, 7:30 AM EDT - 7 months ago

Ocugen to Host Webcast on Wednesday, November 5 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2025 Financial Results

Sep 25, 2025, 9:30 AM EDT - 8 months ago

Ocugen Transcript: H.C. Wainwright – Biotech "On Tap" 2025

Sep 15, 2025, 6:03 AM EDT - 9 months ago

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Sep 2, 2025, 7:02 AM EDT - 9 months ago

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025

Aug 13, 2025, 6:27 AM EDT - 10 months ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

Aug 12, 2025, 3:45 PM EDT - 10 months ago

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 8, 2025, 5:03 PM EDT - 10 months ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

Aug 1, 2025, 8:30 AM EDT - 10 months ago

Ocugen Earnings Call Transcript: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 10 months ago

Ocugen Quarterly report: Q2 2025

Aug 1, 2025, 8:30 AM EDT - 10 months ago

Ocugen Earnings release: Q2 2025

Aug 1, 2025, 8:25 AM EDT - 10 months ago

Ocugen Provides Business Update with Second Quarter 2025 Financial Results

Jul 21, 2025, 7:30 AM EDT - 11 months ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team

Jul 18, 2025, 7:02 AM EDT - 11 months ago

Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease

Jul 17, 2025, 6:30 AM EDT - 11 months ago

Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results

Jun 23, 2025, 7:30 AM EDT - 1 year ago

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases

Jun 16, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease

Jun 11, 2025, 7:30 AM EDT - 1 year ago

Ocugen To Present at BIO International Convention 2025

Jun 5, 2025, 7:02 AM EDT - 1 year ago

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

May 27, 2025, 7:02 AM EDT - 1 year ago

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings Call Transcript: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Quarterly report: Q1 2025

May 9, 2025, 8:30 AM EDT - 1 year ago

Ocugen Earnings release: Q1 2025

May 9, 2025, 8:01 AM EDT - 1 year ago

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 2, 2025, 8:00 AM EDT - 1 year ago

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

Apr 29, 2025, 7:30 AM EDT - 1 year ago

Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Ocugen Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Ocugen Proxy statement: Proxy Filing

Apr 8, 2025, 8:02 AM EDT - 1 year ago

Ocugen to Present at the 2025 Cell & Gene Meeting on the Med

Mar 18, 2025, 8:02 AM EDT - 1 year ago

Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Earnings Call Transcript: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Annual report: Q4 2024

Mar 5, 2025, 8:30 AM EST - 1 year ago

Ocugen Earnings release: Q4 2024

Mar 5, 2025, 7:02 AM EST - 1 year ago

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 8:46 AM EST - 1 year ago

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Feb 21, 2025, 8:00 AM EST - 1 year ago

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Feb 12, 2025, 7:42 AM EST - 1 year ago

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Feb 3, 2025, 6:30 AM EST - 1 year ago

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Jan 31, 2025, 7:00 AM EST - 1 year ago

Ocugen Registration statement: Registration Filing

Jan 27, 2025, 6:30 AM EST - 1 year ago

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Jan 16, 2025, 7:30 AM EST - 1 year ago

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Djtrush Jun. 4 at 12:52 AM

$OCGN Soon

0 · Reply

Jangalang Jun. 4 at 12:16 AM

$OCGN … We all missed the chance to dump this garbage when it was at or around $2.72. We will not see that price target again for years.

1 · Reply

coolzay Jun. 4 at 12:13 AM

$OCGN MM’s trying to get all those shares , shake the trees , OCGN is not for the weak

0 · Reply

HarryA123 Jun. 4 at 12:09 AM

$OCGN No bottom in sight.

1 · Reply

SmoldyShatStone Jun. 3 at 10:34 PM

1 · Reply

TheObsidiansClaw Jun. 3 at 9:58 PM

$OCGN $BETR $SAVEQ $CADL <<-->>

1 · Reply

Jangalang Jun. 3 at 9:14 PM

$OCGN … this message feed is delusional. The decline will continue until this drops far below $1.00 and they force through a reverse split.

2 · Reply

WayLoSellHi Jun. 3 at 8:59 PM

0 · Reply

focafoca99 Jun. 3 at 8:45 PM

$OCGN designated CFO Rita Johnson‑Greene as its new principal accounting officer after the CAO resignation. https://www.rapidticker.com/news/ocgn-sec-filing-8-k-eaaba9

0 · Reply

Lights1980 Jun. 3 at 8:24 PM

$OCGN $1.85 tomorrow.

1 · Reply

Peter56 Jun. 3 at 7:47 PM

$OCGN can we powerdown the bots?

0 · Reply

TheObsidiansClaw Jun. 3 at 7:36 PM

$PSKY $VTGN $OCGN /\

1 · Reply

3I_ATLAS Jun. 3 at 7:17 PM

$OCGN just nuke the white house fuck em all

0 · Reply

Djtrush Jun. 3 at 7:16 PM

$OCGN Been buying shares on sale today.

0 · Reply

nick2341 Jun. 3 at 7:06 PM

$OCGN worst day so far for years in general. Could only be better tomorrow

0 · Reply

ColdSmkskier Jun. 3 at 6:39 PM

$OCGN maybe Shankar will come up the bribe $$$ required to get anything done with the Felon and this corrupt administration. SofaKing

3 · Reply

luca75 Jun. 3 at 6:14 PM

$OCGN longs remain bullish longterm but you cannot ignore the continued impact of this geopolitical crisis dragging down the broader market! We are caught up in this!!! It’s due to the Complete incompetence and BS on the part of this 🍊A$$HATADMINISTRATION. Something else is nagging at me, the leadership turmoil inside the FDA which I worry will delay approvals. Gas approaching $6-$8/gallon is not going to help things at all!!!🤬😤

1 · Reply

Planetpaprika Jun. 3 at 6:09 PM

$OCGN https://finance.yahoo.com/sectors/healthcare/articles/ocugens-gene-agnostic-eye-therapies-155000412.html

0 · Reply

Idfkytm Jun. 3 at 6:03 PM

$OCGN I like the setup. Will add more if we get the reversal back to the 50 EMA.

1 · Reply

LittleDerwin Jun. 3 at 6:02 PM

$OCGN 750% Upside to Average Price Target is all you need to know. BULLISH AF

0 · Reply

BrunoMonteiro Jun. 3 at 5:51 PM

$OCGN The science is there. The data is building. The market is simply waiting for regulatory confirmation.🤞🏻

0 · Reply

Gr8peApe Jun. 3 at 5:27 PM

$OCGN squeeze....

1 · Reply

Market Cap	467.16M
Revenue (ttm)	4.41M
Net Income (ttm)	-67.85M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,538.55%
Debt to Equity Ratio	5.03

Volume	4,428,800
Avg Vol	7,835,080
Day's Range	N/A - N/A
Shares Out	338.52M
Stochastic %K	69%
Beta	2.30
Analysts	Strong Sell
Price Target	$11.43